title: [Recent progress in vaccines against nicotine addiction].
abstract: Tobacco smoking is a global healthcare problem that poses a substantial and costly health burden. Nicotine is the major constituent responsible for the addiction to tobacco. Current strategies helping tobacco smokers have limited utility in increasing rates of smoking cessation, consequently indicating the need for alternative therapies. A novel therapeutic method is vaccination against nicotine. Nicotine vaccine can generate specific antibodies that can sequester nicotine from cigarette smoke in the blood, and prevent its access to the brain and minimize positive reinforcing effects, which may help smokers to stop smoking. The vaccine will have great potential for the treatment of nicotine addiction and for relapse prevention. Here we will review the current status of vaccines against nicotine addiction and discuss the problems associated with the development of nicotine vaccines.
authors.affiliation: Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
authors.forename: Gui-Bin
authors.initials: GB
authors.lastname: Wang
authors.forename: Chuan-Jiang
authors.initials: CJ
authors.lastname: Zhu
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D009538:Nicotine / Q000037:antagonists & inhibitors* / Q000276:immunology; D012907:Smoking / Q000276:immunology / Q000628:therapy; D016540:Smoking Cessation / Q000379:methods; D014029:Tobacco Use Disorder / Q000276:immunology / Q000628:therapy*; D014611:Vaccination / Q000379:methods; D014612:Vaccines / Q000627:therapeutic use*
chemical_list: C557119:NicVAX; C582229:TA-NIC; D014612:Vaccines; C519280:nicotine Qbeta vaccine; D009538:Nicotine